

Bruce R Blazar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6993192/publications.pdf>

Version: 2024-02-01

527
papers

48,200
citations

906
116
h-index

2385
198
g-index

562
all docs

562
docs citations

562
times ranked

39830
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. <i>Journal of Experimental Medicine</i> , 2010, 207, 2187-2194.	8.5	1,652
2	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. <i>Blood</i> , 2005, 105, 3051-3057.	1.4	1,574
3	The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. <i>Blood</i> , 2002, 99, 3493-3499.	1.4	978
4	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. <i>Blood</i> , 2011, 117, 1061-1070.	1.4	926
5	Acute Graft-versus-Host Disease â€” Biologic Process, Prevention, and Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 2167-2179.	27.0	822
6	Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers. <i>New England Journal of Medicine</i> , 2004, 351, 2590-2598.	27.0	791
7	Rescue of exhausted CD8 T cells by PD-1â€”targeted therapies is CD28-dependent. <i>Science</i> , 2017, 355, 1423-1427.	12.6	753
8	Advances in graft-versus-host disease biology and therapy. <i>Nature Reviews Immunology</i> , 2012, 12, 443-458.	22.7	746
9	IL-2 Receptor Î²-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells. <i>Journal of Immunology</i> , 2007, 178, 280-290.	0.8	709
10	Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. <i>Journal of Clinical Investigation</i> , 2007, 117, 2570-2582.	8.2	698
11	Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. <i>Journal of Experimental Medicine</i> , 2012, 209, 903-911.	8.5	552
12	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 141-151.	30.7	539
13	Cd4+Cd25+ Immune Regulatory Cells Are Required for Induction of Tolerance to Alloantigen via Costimulatory Blockade. <i>Journal of Experimental Medicine</i> , 2001, 193, 1311-1318.	8.5	536
14	Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host Disease. <i>Immunity</i> , 2012, 37, 339-350.	14.3	509
15	Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. <i>Blood</i> , 2007, 110, 3064-3070.	1.4	489
16	Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. <i>New England Journal of Medicine</i> , 2017, 377, 2565-2579.	27.0	469
17	Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Annual Review of Immunology</i> , 2007, 25, 139-170.	21.8	454
18	Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. <i>Cell</i> , 2018, 175, 1780-1795.e19.	28.9	445

#	ARTICLE	IF	CITATIONS
19	Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. <i>Science Translational Medicine</i> , 2013, 5, 179ra43.	12.4	401
20	Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning. <i>Immunity</i> , 2009, 30, 656-665.	14.3	400
21	Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2001, 97, 1458-1466.	1.4	396
22	The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation. <i>Journal of Immunology</i> , 2008, 181, 5396-5404.	0.8	394
23	Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. <i>Blood</i> , 2010, 116, 5738-5747.	1.4	384
24	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. <i>Blood</i> , 2014, 123, 3855-3863.	1.4	357
25	Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. <i>Blood</i> , 2002, 100, 3825-3827.	1.4	356
26	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017, 130, 2243-2250.	1.4	352
27	Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells. <i>Stem Cells</i> , 2010, 28, 1446-1455.	3.2	348
28	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. <i>Blood</i> , 2016, 127, 1044-1051.	1.4	333
29	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234.	2.0	328
30	Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa. <i>New England Journal of Medicine</i> , 2010, 363, 629-639.	27.0	326
31	Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T _{regs}) with Minimal Loss of in Vivo Functional Activity. <i>Science Translational Medicine</i> , 2011, 3, 83ra41.	12.4	326
32	L-Selectinhi but not the L-selectinlo CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. <i>Blood</i> , 2004, 104, 3804-3812.	1.4	324
33	Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. <i>Blood</i> , 2012, 119, 3064-3072.	1.4	318
34	Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN- γ -Dependent Mechanism. <i>Journal of Immunology</i> , 2003, 171, 1272-1277.	0.8	305
35	IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, <i>In Vivo</i> Expansion, and Enhanced Function. <i>Clinical Cancer Research</i> , 2016, 22, 3440-3450.	7.0	291
36	Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft. <i>Cell Stem Cell</i> , 2016, 18, 144-155.	11.1	289

#	ARTICLE	IF	CITATIONS
37	Leukocyte migration and graft-versus-host disease. Blood, 2005, 105, 4191-4199.	1.4	287
38	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood, 2009, 113, 3865-3874.	1.4	285
39	Vstm3 is a member of the CD28 family and an important modulator of T cell function. European Journal of Immunology, 2011, 41, 902-915.	2.9	285
40	Cord blood CD4+CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood, 2005, 105, 750-758.	1.4	276
41	In vitro differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood, 2009, 113, 1365-1374.	1.4	272
42	Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood, 2002, 99, 4592-4600.	1.4	265
43	Protein Kinase C- δ Mediates Negative Feedback on Regulatory T Cell Function. Science, 2010, 328, 372-376.	12.6	261
44	Acute graft-versus-host disease: from the bench to the bedside. Blood, 2009, 114, 4327-4336.	1.4	257
45	Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature, 2019, 572, 254-259.	27.8	246
46	Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8120-8125.	7.1	238
47	TALEN-based Gene Correction for Epidermolysis Bullosa. Molecular Therapy, 2013, 21, 1151-1159.	8.2	232
48	The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood, 2003, 102, 303-310.	1.4	229
49	Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood, 2005, 106, 3300-3307.	1.4	227
50	Polyamines and eIF5A Hypusination Modulate Mitochondrial Respiration and Macrophage Activation. Cell Metabolism, 2019, 30, 352-363.e8.	16.2	223
51	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood, 2012, 119, 1570-1580.	1.4	221
52	CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood, 2014, 123, 3016-3026.	1.4	220
53	p27kip1 functions as an energy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nature Medicine, 2000, 6, 290-297.	30.7	216
54	Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood, 2017, 129, 13-21.	1.4	216

#	ARTICLE	IF	CITATIONS
55	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
56	Mitochondrial Integrity Regulated by Lipid Metabolism Is a Cell-Intrinsic Checkpoint for Treg Suppressive Function. <i>Cell Metabolism</i> , 2020, 31, 422-437.e5.	16.2	215
57	PD-1 blockade for relapsed lymphoma postâ€“allogeneic hematopoietic cell transplant: high response rate but frequent CVHD. <i>Blood</i> , 2017, 130, 221-228.	1.4	214
58	The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8+ T cells. <i>Nature</i> , 2018, 559, 264-268.	27.8	209
59	Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. <i>Blood</i> , 2007, 109, 2529-2537.	1.4	208
60	Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. <i>Blood</i> , 2005, 105, 2227-2234.	1.4	201
61	Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. <i>Blood</i> , 2002, 100, 682-691.	1.4	197
62	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
63	Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. <i>Nature Communications</i> , 2019, 10, 567.	12.8	193
64	Generation and Large-Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft-Versus-Host Disease. <i>American Journal of Transplantation</i> , 2011, 11, 1148-1157.	4.7	192
65	Long-term outcome of Hurler syndrome following bone marrow transplantation. <i>American Journal of Medical Genetics Part A</i> , 1993, 46, 209-218.	2.4	190
66	Engineering lymphocyte subsets: tools, trials and tribulations. <i>Nature Reviews Immunology</i> , 2009, 9, 704-716.	22.7	185
67	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16814-16819.	7.1	185
68	IL-33 Is an Unconventional Alarmin That Stimulates IL-2 Secretion by Dendritic Cells To Selectively Expand IL-33R/ST2+ Regulatory T Cells. <i>Journal of Immunology</i> , 2014, 193, 4010-4020.	0.8	185
69	Thymic T-cell development in allogeneic stem cell transplantation. <i>Blood</i> , 2011, 117, 6768-6776.	1.4	184
70	Chimeric Antigen Receptor T Cellâ€“Mediated Neurotoxicity in Nonhuman Primates. <i>Cancer Discovery</i> , 2018, 8, 750-763.	9.4	184
71	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	1.4	179
72	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 130-137.	1.4	176

#	ARTICLE	IF	CITATIONS
73	Follicular regulatory T cells control humoral and allergic immunity by restraining early B cell responses. <i>Nature Immunology</i> , 2019, 20, 1360-1371.	14.5	176
74	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	8.2	173
75	CSF-1 α -dependant donor-derived macrophages mediate chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4266-4280.	8.2	173
76	Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. <i>Molecular Therapy</i> , 2016, 24, 570-581.	8.2	168
77	Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. <i>Blood</i> , 2002, 100, 3479-3482.	1.4	167
78	The PTEN pathway in T χ regs is a critical driver of the suppressive tumor microenvironment. <i>Science Advances</i> , 2015, 1, e1500845.	10.3	167
79	Oncogenic JAK2 χ V617F χ causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	166
80	MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. <i>Immunity</i> , 2019, 51, 885-898.e7.	14.3	164
81	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1970-1980.	5.2	164
82	Donor CD4 χ Foxp3 χ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. <i>Blood</i> , 2014, 124, 2131-2141.	1.4	162
83	IL-10 and TGF- χ induce alloreactive CD4 χ CD25 χ T cells to acquire regulatory cell function. <i>Blood</i> , 2003, 101, 5076-5083.	1.4	161
84	The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo. <i>Journal of Immunology</i> , 2011, 187, 1097-1105.	0.8	159
85	An Inherently Bifunctional Subset of Foxp3 χ T Helper Cells Is Controlled by the Transcription Factor Eos. <i>Immunity</i> , 2013, 38, 998-1012.	14.3	159
86	Reprogrammed Foxp3 χ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8 χ T Cell Priming in Naive Mice. <i>Immunity</i> , 2010, 33, 942-954.	14.3	157
87	Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. <i>Blood</i> , 2013, 122, 3062-3073.	1.4	156
88	VISTA is a checkpoint regulator for na χ ve T cell quiescence and peripheral tolerance. <i>Science</i> , 2020, 367, .	12.6	156
89	PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	151
90	Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). <i>Blood</i> , 2006, 108, 3216-3222.	1.4	147

#	ARTICLE	IF	CITATIONS
91	CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR β repertoire. <i>Blood</i> , 2015, 125, 3835-3850.	1.4	147
92	Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2016, 76, 5696-5706.	0.9	146
93	Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. <i>Blood</i> , 2008, 111, 3257-3265.	1.4	145
94	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016, 127, 2144-2154.	1.4	145
95	Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. <i>Blood</i> , 2011, 117, 3268-3276.	1.4	143
96	Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. <i>Blood</i> , 2009, 114, 3793-3802.	1.4	140
97	Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. <i>Blood</i> , 2001, 97, 3132-3137.	1.4	139
98	Induced Pluripotent Stem Cells from Individuals with Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2011, 131, 848-856.	0.7	139
99	Ligation of 4-1BB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients. <i>Journal of Immunology</i> , 2001, 166, 3174-3183.	0.8	135
100	Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3202-3208.	1.6	135
101	Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 40-46.	2.0	134
102	Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. <i>Blood</i> , 2008, 112, 2847-2857.	1.4	134
103	The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. <i>Blood</i> , 2015, 125, 3183-3192.	1.4	133
104	iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti- α PD-1 therapy. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	133
105	In vivo imaging of graft-versus-host-disease in mice. <i>Blood</i> , 2004, 103, 3590-3598.	1.4	132
106	IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. <i>Blood</i> , 2009, 114, 5375-5384.	1.4	132
107	Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5460-5465.	7.1	131
108	ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. <i>Science Translational Medicine</i> , 2015, 7, 308ra160.	12.4	131

#	ARTICLE	IF	CITATIONS
109	Keratinocyte Growth Factor Administered Before Conditioning Ameliorates Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation in Mice. <i>Blood</i> , 1998, 92, 3960-3967.	1.4	130
110	Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting. <i>Journal of Clinical Oncology</i> , 2006, 24, 5186-5193.	1.6	130
111	Recent advances in graft-versus-host disease (GVHD) prevention. <i>Immunological Reviews</i> , 1997, 157, 79-109.	6.0	129
112	Regulation of acute graft-versus-host disease by microRNA-155. <i>Blood</i> , 2012, 119, 4786-4797.	1.4	128
113	Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. <i>Blood</i> , 2002, 99, 4601-4609.	1.4	126
114	Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells. <i>Journal of Experimental Medicine</i> , 2007, 204, 129-139.	8.5	126
115	Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. <i>JCI Insight</i> , 2016, 1, e89278.	5.0	126
116	Chronic stimulation drives human NK cell dysfunction and epigenetic reprogramming. <i>Journal of Clinical Investigation</i> , 2019, 129, 3770-3785.	8.2	125
117	Differential Roles for CCR5 Expression on Donor T Cells during Graft-versus-Host Disease Based on Pretransplant Conditioning. <i>Journal of Immunology</i> , 2004, 173, 845-854.	0.8	124
118	Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. <i>Journal of Experimental Medicine</i> , 2014, 211, 2373-2383.	8.5	124
119	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021, 138, 2278-2289.	1.4	124
120	Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. <i>Blood</i> , 2009, 114, 5062-5070.	1.4	123
121	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. <i>JCI Insight</i> , 2018, 3, .	5.0	123
122	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- β 2 production. <i>Blood</i> , 2017, 129, 2570-2580.	1.4	122
123	Eomesodermin promotes the development of type 1 regulatory T (T _H 1) cells. <i>Science Immunology</i> , 2017, 2, .	11.9	118
124	Retinoic Acid and Rapamycin Differentially Affect and Synergistically Promote the Ex Vivo Expansion of Natural Human T Regulatory Cells. <i>PLoS ONE</i> , 2011, 6, e15868.	2.5	118
125	The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo. <i>Journal of Immunology</i> , 2011, 187, 1113-1119.	0.8	115
126	Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses through the PD-1/PD-L1 Axis. <i>Cancer Research</i> , 2014, 74, 3441-3453.	0.9	115

#	ARTICLE	IF	CITATIONS
127	GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. Cancer Research, 2017, 77, 5664-5675.	0.9	114
128	Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood, 2005, 105, 3372-3380.	1.4	113
129	Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. Blood, 2018, 131, 2651-2660.	1.4	113
130	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. Journal of Clinical Oncology, 2021, 39, 1865-1877.	1.6	111
131	Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood, 2005, 106, 3293-3299.	1.4	110
132	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood, 2013, 122, 1510-1517.	1.4	104
133	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood, 2015, 126, 1621-1628.	1.4	104
134	Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. British Journal of Haematology, 2016, 175, 191-207.	2.5	103
135	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood, 2015, 125, 4085-4094.	1.4	101
136	Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood, 2003, 101, 3741-3748.	1.4	100
137	Engraftment of Severe Combined Immune Deficient Mice Receiving Allogeneic Bone Marrow Via In Utero or Postnatal Transfer. Blood, 1998, 92, 3949-3959.	1.4	98
138	ARID5B regulates metabolic programming in human adaptive NK cells. Journal of Experimental Medicine, 2018, 215, 2379-2395.	8.5	98
139	A New Murine Model for Bronchiolitis Obliterans Post-Bone Marrow Transplant. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 713-723.	5.6	97
140	Clinical perspectives for regulatory T cells in transplantation tolerance. Seminars in Immunology, 2011, 23, 462-468.	5.6	95
141	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood, 2016, 128, 1013-1017.	1.4	95
142	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. Immunity, 2018, 48, 91-106.e6.	14.3	95
143	Fanconi Anemia Gene Editing by the CRISPR/Cas9 System. Human Gene Therapy, 2015, 26, 114-126.	2.7	94
144	Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood, 2018, 131, 1858-1869.	1.4	94

#	ARTICLE	IF	CITATIONS
145	Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. <i>Blood</i> , 2001, 98, 467-474.	1.4	93
146	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 2489-2497.	1.4	92
147	Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. <i>Nature Communications</i> , 2020, 11, 1659.	12.8	92
148	Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. <i>Blood</i> , 2000, 96, 4350-4356.	1.4	91
149	Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. <i>Blood</i> , 2016, 128, 427-439.	1.4	91
150	Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. <i>Blood</i> , 2002, 100, 3400-3407.	1.4	90
151	Alternative donor hematopoietic cell transplantation for Fanconi anemia. <i>Blood</i> , 2015, 125, 3798-3804.	1.4	90
152	Minimal PD-1 expression in mouse and human NK cells under diverse conditions. <i>Journal of Clinical Investigation</i> , 2020, 130, 3051-3068.	8.2	90
153	Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. <i>Science Translational Medicine</i> , 2015, 7, 280rv2.	12.4	88
154	B Cells in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 16-23.	2.0	86
155	INTERLEUKIN-10 DOSE-DEPENDENT REGULATION OF CD4+ AND CD8+ T CELL-MEDIATED GRAFT-VERSUS-HOST DISEASE1. <i>Transplantation</i> , 1998, 66, 1220-1229.	1.0	86
156	Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. <i>JCI Insight</i> , 2019, 4, .	5.0	86
157	161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. <i>Blood Advances</i> , 2018, 2, 1459-1469.	5.2	85
158	STAT3 Signaling in CD4+ T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model. <i>Journal of Immunology</i> , 2010, 184, 764-774.	0.8	84
159	Systemic Delivery of <i>Salmonella typhimurium</i> Transformed with IDO shRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth. <i>Cancer Research</i> , 2012, 72, 6447-6456.	0.9	84
160	Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 1813-1825.	8.2	84
161	ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2021, 39, 1888-1898.	1.6	83
162	Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). <i>Blood</i> , 2011, 117, 839-847.	1.4	82

#	ARTICLE	IF	CITATIONS
163	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. <i>Journal of Clinical Investigation</i> , 2016, 126, 2642-2660.	8.2	81
164	Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 475-492.	27.6	80
165	Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. <i>Cell Stem Cell</i> , 2021, 28, 2062-2075.e5.	11.1	80
166	Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. <i>Blood</i> , 2012, 119, 619-628.	1.4	79
167	Current Concepts and Advances in Graft-Versus-Host Disease Immunology. <i>Annual Review of Immunology</i> , 2021, 39, 19-49.	21.8	79
168	CD30/CD30 Ligand (CD153) Interaction Regulates CD4+ T Cell-Mediated Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2004, 173, 2933-2941.	0.8	77
169	Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. <i>Blood Advances</i> , 2018, 2, 909-922.	5.2	76
170	Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. <i>Blood</i> , 2008, 111, 5242-5251.	1.4	75
171	TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. <i>Blood</i> , 2008, 112, 3508-3516.	1.4	75
172	Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. <i>Cancer Immunology Research</i> , 2018, 6, 766-775.	3.4	75
173	PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. <i>Blood</i> , 2011, 117, 1030-1041.	1.4	74
174	Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. <i>Blood</i> , 2012, 120, 2229-2239.	1.4	74
175	CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. <i>Npj Regenerative Medicine</i> , 2016, 1, .	5.2	74
176	How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. <i>Blood Advances</i> , 2018, 2, 2012-2019.	5.2	74
177	The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation. <i>Nature Communications</i> , 2019, 10, 354.	12.8	74
178	Cytokine mediators of chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 2452-2463.	8.2	74
179	Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. <i>Blood</i> , 2004, 103, 1158-1165.	1.4	73
180	Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation. <i>Blood</i> , 2015, 125, 2435-2444.	1.4	73

#	ARTICLE	IF	CITATIONS
181	Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. <i>British Journal of Haematology</i> , 1997, 96, 749-756.	2.5	72
182	Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). <i>Blood</i> , 2007, 110, 3480-3488.	1.4	72
183	Treatment of chronic graft-versus-host disease with bortezomib. <i>Blood</i> , 2014, 124, 1677-1688.	1.4	72
184	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	1.2	72
185	Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. <i>Journal of Clinical Investigation</i> , 2017, 127, 1574-1588.	8.2	72
186	Host T Cells Resist Graft-Versus-Host Disease Mediated by Donor Leukocyte Infusions. <i>Journal of Immunology</i> , 2000, 165, 4901-4909.	0.8	71
187	Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine Administration: Implications for Clinical Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1252-1257.	2.0	71
188	Patient-Specific Naturally Gene-Reverted Induced Pluripotent Stem Cells in Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1246-1254.	0.7	70
189	miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. <i>Blood</i> , 2016, 128, 1424-1435.	1.4	70
190	CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration. <i>Science Immunology</i> , 2019, 4, .	11.9	70
191	Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	70
192	PKC δ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 3774-3786.	8.2	70
193	Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs. <i>Journal of Investigative Dermatology</i> , 2020, 140, 338-347.e5.	0.7	69
194	PKC- δ function at the immunological synapse: prospects for therapeutic targeting. <i>Trends in Immunology</i> , 2011, 32, 358-363.	6.8	68
195	Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?. <i>Blood</i> , 2016, 127, 3117-3126.	1.4	68
196	Blockade of LIGHT/LT β and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2002, 109, 549-557.	8.2	68
197	GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28 α^{hi} CD8 $^{+}$ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression. <i>Blood</i> , 2010, 116, 5403-5418.	1.4	67
198	Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. <i>Journal of Immunology</i> , 2018, 200, 3926-3933.	0.8	67

#	ARTICLE	IF	CITATIONS
199	Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1017-1021.	2.0	65
200	Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. <i>Science Translational Medicine</i> , 2015, 7, 315ra191.	12.4	64
201	Increasing Regulatory T Cells With Interleukin-2 and Interleukin-2 Antibody Complexes Attenuates Lung Inflammation and Heart Failure Progression. <i>Hypertension</i> , 2016, 68, 114-122.	2.7	64
202	Therapeutic activity of multiple common γ -chain cytokine inhibition in acute and chronic GVHD. <i>Blood</i> , 2015, 125, 570-580.	1.4	63
203	Acute graft-versus-host disease is regulated by an IL-17 α -sensitive microbiome. <i>Blood</i> , 2017, 129, 2172-2185.	1.4	63
204	Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. <i>Blood</i> , 2017, 129, 3121-3125.	1.4	63
205	The Role of B7 Costimulation by Murine Acute Myeloid Leukemia in the Generation and Function of a CD8 $^{+}$ T-Cell Line With Potent In Vivo Graft-Versus-Leukemia Properties. <i>Blood</i> , 1997, 89, 3477-3485.	1.4	62
206	TRAF6 directs FOXP3 localization and facilitates regulatory T cell function through K63-linked ubiquitination. <i>EMBO Journal</i> , 2019, 38, .	7.8	62
207	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	1.2	62
208	An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. <i>Experimental Hematology</i> , 2004, 32, 318-324.	0.4	60
209	Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. <i>Blood</i> , 2020, 136, 1442-1455.	1.4	60
210	A phase II trial of human recombinant Interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study. <i>Cancer</i> , 1995, 75, 2959-2965.	4.1	59
211	Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. <i>Blood</i> , 2015, 125, 1502-1506.	1.4	59
212	Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9334-9344.	6.4	59
213	Combined OX40L and mTOR blockade controls effector T cell activation while preserving T $_{\text{reg}}$ reconstitution after transplant. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	59
214	Adaptive NK cell reconstitution is associated with better clinical outcomes. <i>JCI Insight</i> , 2019, 4, .	5.0	59
215	CD154 on the surface of CD4 $^{+}$ CD25 $^{+}$ regulatory t cells contributes to skin transplant tolerance. <i>Transplantation</i> , 2003, 76, 1375-1379.	1.0	58
216	CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease. <i>Blood</i> , 2013, 122, 825-836.	1.4	58

#	ARTICLE	IF	CITATIONS
217	Cutting Edge: TGF- β 2 and Phosphatidylinositol 3-Kinase Signals Modulate Distinct Metabolism of Regulatory T Cell Subsets. <i>Journal of Immunology</i> , 2018, 201, 2215-2219.	0.8	58
218	A trisppecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. <i>Leukemia</i> , 2021, 35, 1586-1596.	7.2	57
219	Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005, 360, 1747-1767.	4.0	56
220	FoxP3 and Ezh2 regulate Tfr cell suppressive function and transcriptional program. <i>Journal of Experimental Medicine</i> , 2019, 216, 605-620.	8.5	56
221	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. <i>Blood</i> , 2015, 125, 3335-3346.	1.4	55
222	Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. <i>Nature Communications</i> , 2016, 7, 12021.	12.8	54
223	Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF- β -Dependent Intensification of Oxidative Stress and Tumor Cell Death. <i>Cell Metabolism</i> , 2018, 28, 228-242.e6.	16.2	54
224	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017, 2, .	5.0	53
225	Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells. <i>Blood</i> , 2010, 115, 4914-4922.	1.4	52
226	B-cell targeting in chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 1399-1405.	1.4	52
227	Notch Signaling at Later Stages of NK Cell Development Enhances KIR Expression and Functional Maturation. <i>Journal of Immunology</i> , 2014, 193, 3344-3354.	0.8	51
228	MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. <i>Blood</i> , 2018, 131, 1974-1986.	1.4	51
229	Ribosome-Targeting Antibiotics Impair T Cell Effector Function and Ameliorate Autoimmunity by Blocking Mitochondrial Protein Synthesis. <i>Immunity</i> , 2021, 54, 68-83.e6.	14.3	51
230	Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. <i>Blood</i> , 2016, 128, 794-804.	1.4	49
231	Maintenance of CD4 T cell fitness through regulation of Foxo1. <i>Nature Immunology</i> , 2018, 19, 838-848.	14.5	49
232	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. <i>Blood</i> , 2019, 134, 1670-1682.	1.4	49
233	Attenuation of Acute Graft-versus-Host Disease in the Absence of the Transcription Factor ROR γ t. <i>Journal of Immunology</i> , 2012, 189, 1765-1772.	0.8	48
234	A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1737-1743.	2.0	48

#	ARTICLE	IF	CITATIONS
235	Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. <i>Blood</i> , 2012, 120, 682-690.	1.4	47
236	Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. <i>Blood</i> , 2013, 122, 2125-2134.	1.4	47
237	Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. <i>Onc Immunology</i> , 2016, 5, e1075114.	4.6	47
238	Altered T-cell receptor+CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-treated alloreactive T cells that do not induce graft-versus-host disease. <i>Blood</i> , 2001, 97, 565-571.	1.4	46
239	Peyer patches are not required for acute graft-versus-host disease after myeloablative conditioning and murine allogeneic bone marrow transplantation. <i>Blood</i> , 2006, 107, 410-412.	1.4	46
240	Cutting Edge: Identification of Autoreactive CD4+ and CD8+ T Cell Subsets Resistant to PD-1 Pathway Blockade. <i>Journal of Immunology</i> , 2015, 194, 3551-3555.	0.8	46
241	Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells. <i>Blood</i> , 2016, 128, 2568-2579.	1.4	46
242	Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 57.	4.8	46
243	Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. <i>JCI Insight</i> , 2019, 4, .	5.0	46
244	Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	46
245	Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells. <i>Experimental Hematology</i> , 2006, 34, 66-71.	0.4	45
246	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 668-675.	2.0	45
247	A critical role for donor-derived IL-22 in cutaneous chronic GVHD. <i>American Journal of Transplantation</i> , 2018, 18, 810-820.	4.7	45
248	Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. <i>Nature Communications</i> , 2018, 9, 5193.	12.8	45
249	Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. <i>Blood</i> , 2011, 117, 7032-7041.	1.4	44
250	Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells. <i>Blood</i> , 2016, 127, 1930-1939.	1.4	44
251	ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings. <i>Science Signaling</i> , 2016, 9, ra73.	3.6	44
252	Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. <i>Immunological Reviews</i> , 2017, 276, 192-212.	6.0	44

#	ARTICLE	IF	CITATIONS
253	Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2377-2392.	6.1	44
254	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019, 3, 2550-2561.	5.2	44
255	Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: Effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 277-284.	2.0	43
256	Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. <i>JCI Insight</i> , 2016, 1, e86850.	5.0	43
257	Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. <i>Journal of Immunology</i> , 2017, 198, 2500-2512.	0.8	43
258	Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy. , 2017, 5, 33.		43
259	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. <i>Frontiers in Immunology</i> , 2017, 8, 1844.	4.8	43
260	Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. <i>Cancer Gene Therapy</i> , 2020, 27, 235-245.	4.6	42
261	CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates. <i>Journal of Clinical Investigation</i> , 2018, 128, 3991-4007.	8.2	42
262	The Balance Between Donor T Cell Anergy and Suppression Versus Lethal Graft-Versus-Host Disease Is Determined by Host Conditioning. <i>Journal of Immunology</i> , 2002, 169, 5581-5589.	0.8	41
263	Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 962-969.	2.0	41
264	Stromal cellâ€‘derived factor-1 and hematopoietic cell homing in an adult zebrafish model of hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 766-774.	1.4	41
265	Optimization of cGMP purification and expansion of umbilical cord bloodâ€‘derived T-regulatory cells in support of first-in-human clinical trials. <i>Cytotherapy</i> , 2017, 19, 250-262.	0.7	41
266	Persistent STAT5 activation reprograms the epigenetic landscape in CD4 ⁺ T cells to drive polyfunctionality and antitumor immunity. <i>Science Immunology</i> , 2020, 5, .	11.9	40
267	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. <i>Blood Advances</i> , 2021, 5, 1425-1436.	5.2	39
268	Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8 ⁺ T cells drive gastrointestinal acute graft-versus-host disease. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	39
269	Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+IL17+ response. , 2014, 2, 4.		38
270	Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced ILâ€‘22 production and ILâ€‘2â€‘dependent proliferation. <i>European Journal of Immunology</i> , 2015, 45, 2335-2342.	2.9	38

#	ARTICLE	IF	CITATIONS
271	Increased Effector Memory Insulin-Specific CD4+ T Cells Correlate With Insulin Autoantibodies in Patients With Recent-Onset Type 1 Diabetes. <i>Diabetes</i> , 2017, 66, 3051-3060.	0.6	38
272	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. <i>Blood</i> , 2017, 130, 2131-2145.	1.4	37
273	miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg). <i>Cell Death and Disease</i> , 2018, 9, 290.	6.3	37
274	Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. <i>Molecular Therapy</i> , 2018, 26, 1423-1434.	8.2	37
275	Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. <i>JCI Insight</i> , 2016, 1, .	5.0	37
276	Chemokine treatment rescues profound T-lineage progenitor homing defect after bone marrow transplant conditioning in mice. <i>Blood</i> , 2014, 124, 296-304.	1.4	36
277	Isoform-specific targeting of ROCK proteins in immune cells. <i>Small GTPases</i> , 2016, 7, 173-177.	1.6	36
278	Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. <i>JCI Insight</i> , 2020, 5, .	5.0	35
279	Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia. <i>Journal of Clinical Investigation</i> , 2020, 130, 1315-1329.	8.2	35
280	Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 α (CCL3) after allogeneic BMT in mice. <i>Blood</i> , 2003, 101, 3714-3721.	1.4	34
281	Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. <i>Immunity</i> , 2021, 54, 2354-2371.e8.	14.3	34
282	Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethality. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 197-207.	2.0	33
283	Pig Embryonic Pancreatic Tissue as a Source for Transplantation in Diabetes. <i>Diabetes</i> , 2009, 58, 1585-1594.	0.6	33
284	Keratinocytes from Induced Pluripotent Stem Cells in Junctional Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2013, 133, 562-565.	0.7	33
285	Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation. <i>Journal of Leukocyte Biology</i> , 2017, 102, 335-341.	3.3	32
286	GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity. <i>Blood</i> , 2017, 129, 630-642.	1.4	32
287	Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2297-2302.	2.0	32
288	Blockade of LIGHT/LT β and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2002, 109, 549-557.	8.2	32

#	ARTICLE	IF	CITATIONS
289	The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 4604-4621.	8.2	32
290	Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease. <i>Trends in Immunology</i> , 2020, 41, 77-91.	6.8	31
291	Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice. <i>Blood</i> , 2018, 132, 2188-2200.	1.4	30
292	Licensing delineates helper and effector NK cell subsets during viral infection. <i>JCI Insight</i> , 2017, 2, .	5.0	30
293	Obesity induces gut microbiota alterations and augments acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	29
294	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	1.2	29
295	Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and rapamycin. <i>Experimental Hematology</i> , 2006, 34, 802-808.	0.4	28
296	Prevention of Graft-versus-Host Disease by Adoptive T Regulatory Therapy Is Associated with Active Repression of Peripheral Blood Toll-Like Receptor 5 mRNA Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 173-182.	2.0	28
297	CD8-predominant T-cell CNS infiltration accompanies GVHD in primates and is improved with immunoprophylaxis. <i>Blood</i> , 2014, 123, 1967-1969.	1.4	28
298	The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. <i>Current Topics in Microbiology and Immunology</i> , 2015, 395, 225-243.	1.1	28
299	Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease. <i>Frontiers in Immunology</i> , 2019, 10, 309.	4.8	28
300	IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer. <i>Blood Advances</i> , 2020, 4, 1594-1605.	5.2	28
301	Follicular T cells mediate donor-specific antibody and rejection after solid organ transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 1893-1901.	4.7	28
302	Regulatory T cells. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 46-49.	2.0	27
303	Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2025-2030.	2.0	27
304	In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. <i>American Journal of Transplantation</i> , 2017, 17, 3098-3113.	4.7	27
305	A robust in vitro model for trans-lymphatic endothelial migration. <i>Scientific Reports</i> , 2017, 7, 1633.	3.3	27
306	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	5.2	27

#	ARTICLE	IF	CITATIONS
307	Regulatory T Cells Condition Lymphatic Endothelia for Enhanced Transendothelial Migration. <i>Cell Reports</i> , 2020, 30, 1052-1062.e5.	6.4	27
308	Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 4652-4662.	8.2	27
309	Effect of Sepsis Syndrome on Neonatal Protein and Energy Metabolism. <i>Journal of Perinatology</i> , 2000, 20, 96-100.	2.0	26
310	Bystander Activation and Anti-Tumor Effects of CD8+ T Cells Following Interleukin-2 Based Immunotherapy Is Independent of CD4+ T Cell Help. <i>PLoS ONE</i> , 2014, 9, e102709.	2.5	26
311	Differential Regulation of T-cell Immunity and Tolerance by Stromal Laminin Expressed in the Lymph Node. <i>Transplantation</i> , 2019, 103, 2075-2089.	1.0	26
312	ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. <i>Clinical Immunology</i> , 2021, 230, 108823.	3.2	26
313	Analysis of the Requirements for the Induction of CD4+ T Cell Alloantigen Hyporesponsiveness by Ex Vivo Anti-CD40 Ligand Antibody. <i>Journal of Immunology</i> , 2000, 164, 612-622.	0.8	25
314	T-cell expression of AhR inhibits the maintenance of pTreg cells in the gastrointestinal tract in acute GVHD. <i>Blood</i> , 2017, 130, 348-359.	1.4	25
315	IDO in Human Gut Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 150-155.	2.0	24
316	Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1899-1904.	2.0	24
317	CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. <i>Stem Cells and Development</i> , 2016, 25, 1591-1603.	2.1	24
318	MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. <i>Journal of Immunology</i> , 2018, 200, 4170-4179.	0.8	24
319	VISTA Re-programs Macrophage Biology Through the Combined Regulation of Tolerance and Anti-inflammatory Pathways. <i>Frontiers in Immunology</i> , 2020, 11, 580187.	4.8	24
320	CRISPR/Cas9-Based Lateral Flow and Fluorescence Diagnostics. <i>Bioengineering</i> , 2021, 8, 23.	3.5	24
321	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	1.2	24
322	C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans. <i>JCI Insight</i> , 2018, 3, .	5.0	24
323	Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 879-883.	2.0	23
324	Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T ^H cells and hematopoietic stem and progenitor cells using base editing. <i>Molecular Therapy</i> , 2022, 30, 130-144.	8.2	23

#	ARTICLE	IF	CITATIONS
325	Unrelated Donor Bone Marrow Transplantation for Hematological Malignancies-Current Status. Leukemia and Lymphoma, 1996, 23, 221-226.	1.3	22
326	Programming of donor T cells using allogeneic $\hat{\text{I}}$ -like ligand 4 $\hat{\text{I}}$ “positive dendritic cells to reduce GVHD in mice. Blood, 2016, 127, 3270-3280.	1.4	22
327	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. JHEP Reports, 2022, 4, 100386.	4.9	22
328	Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling. Cancer Research, 2016, 76, 6802-6815.	0.9	21
329	B Cells Drive Autoimmunity in Mice with CD28-Deficient Regulatory T Cells. Journal of Immunology, 2017, 199, 3972-3980.	0.8	21
330	Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood, 2018, 131, 1743-1754.	1.4	21
331	Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets. PLoS ONE, 2019, 14, e0217761.	2.5	21
332	Reduction in murine acute GVHD severity by human gingival tissue-derived mesenchymal stem cells via the CD39 pathways. Cell Death and Disease, 2019, 10, 13.	6.3	21
333	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood, 2019, 133, 94-99.	1.4	21
334	IFN- $\hat{\text{I}}$ » therapy prevents severe gastrointestinal graft-versus-host disease. Blood, 2021, 138, 722-737.	1.4	21
335	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 632-641.	1.2	21
336	The lymph node stromal laminin $\hat{\text{I}}$ \pm 5 shapes alloimmunity. Journal of Clinical Investigation, 2020, 130, 2602-2619.	8.2	21
337	Osteosarcoma Derived from Cultured Mesenchymal Stem Cells.. Blood, 2006, 108, 2554-2554.	1.4	21
338	Understanding Chronic GVHD from Different Angles. Biology of Blood and Marrow Transplantation, 2012, 18, S184-S188.	2.0	20
339	Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. Haematologica, 2016, 101, 764-772.	3.5	20
340	Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant. , 2016, 4, 11.		20
341	IL-7 signaling imparts polyfunctionality and stemness potential to CD4 ⁺ T cells. Oncoimmunology, 2016, 5, e1171445.	4.6	20
342	Acute Graft-versus-Host Disease. New England Journal of Medicine, 2018, 378, 585-586.	27.0	20

#	ARTICLE	IF	CITATIONS
343	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. <i>Blood Advances</i> , 2021, 5, 1069-1080.	5.2	20
344	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2887.	4.8	19
345	CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 946.	4.1	19
346	Effective Multi-lineage Engraftment in a Mouse Model of Fanconi Anemia Using Non-genotoxic Antibody-Based Conditioning. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 455-464.	4.1	19
347	A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice. <i>Blood</i> , 2022, 139, 1743-1759.	1.4	19
348	Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 804-811.	2.0	18
349	Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol. <i>Cytotherapy</i> , 2019, 21, 1216-1233.	0.7	18
350	Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease. <i>JCI Insight</i> , 2019, 4, .	5.0	18
351	Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease. <i>JCI Insight</i> , 2019, 4, .	5.0	18
352	T cell progenitor therapy“facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction. <i>JCI Insight</i> , 2017, 2, .	5.0	18
353	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. <i>Nature Communications</i> , 2022, 13, 2176.	12.8	18
354	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 2889-2899.	1.4	17
355	Pediatric acute GVHD: clinical phenotype and response to upfront steroids. <i>Bone Marrow Transplantation</i> , 2020, 55, 165-171.	2.4	17
356	GCNT1-Mediated <i>O</i> -Glycosylation of the Sialomucin CD43 Is a Sensitive Indicator of Notch Signaling in Activated T Cells. <i>Journal of Immunology</i> , 2020, 204, 1674-1688.	0.8	17
357	Intestinal Helminths Regulate Lethal Acute Graft-versus-Host Disease and Preserve the Graft-versus-Tumor Effect in Mice. <i>Journal of Immunology</i> , 2015, 194, 1011-1020.	0.8	16
358	Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	16
359	Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9676.	4.1	16
360	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.	3.5	15

#	ARTICLE	IF	CITATIONS
361	Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. Blood Advances, 2018, 2, 2307-2319.	5.2	15
362	ICOSL ⁺ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist. Science Translational Medicine, 2020, 12, .	12.4	15
363	STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets. Science Translational Medicine, 2020, 12, .	12.4	15
364	Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions. Journal of Pediatrics, 2020, 223, 183-185.	1.8	15
365	Effect of Radiation Dose-Rate on Hematopoietic Cell Engraftment in Adult Zebrafish. PLoS ONE, 2013, 8, e73745.	2.5	14
366	Nfatc2 and Tob1 Have Non-Overlapping Function in T Cell Negative Regulation and Tumorigenesis. PLoS ONE, 2014, 9, e100629.	2.5	14
367	A Functional Bioluminescent Zebrafish Screen for Enhancing Hematopoietic Cell Homing. Stem Cell Reports, 2017, 8, 177-190.	4.8	14
368	Generation and function of progenitor T cells from StemRegenin-1 ⁺ expanded CD34 ⁺ human hematopoietic progenitor cells. Blood Advances, 2019, 3, 2934-2948.	5.2	14
369	Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. Biomedicines, 2020, 8, 617.	3.2	14
370	Validation of Minnesota acute graft-versus-host disease Risk Score. Haematologica, 2020, 105, 519-524.	3.5	14
371	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood, 2020, 135, 28-40.	1.4	14
372	Donor bone marrow ⁺ derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice. Blood, 2022, 139, 1389-1408.	1.4	14
373	<i>sdfl</i> Expression Reveals a Source of Perivascular-Derived Mesenchymal Stem Cells in Zebrafish. Stem Cells, 2014, 32, 2767-2779.	3.2	13
374	Preclinical Testing of Antihuman CD28 Fab ⁺ Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease. Transplantation, 2016, 100, 2630-2639.	1.0	13
375	Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. Oncoimmunology, 2016, 5, e1160184.	4.6	13
376	Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease. Frontiers in Immunology, 2020, 11, 181.	4.8	13
377	Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biology of Blood and Marrow Transplantation, 2018, 24, 618-622.	2.0	13
378	β 2-Adrenergic receptor activation on donor cells ameliorates acute GvHD. JCI Insight, 2020, 5, .	5.0	13

#	ARTICLE	IF	CITATIONS
379	Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 281-289.	3.6	12
380	Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells. <i>Blood</i> , 2019, 134, 776-781.	1.4	12
381	Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity. <i>JCI Insight</i> , 2020, 5, .	5.0	12
382	Antibodies to CD40 Promote Dendritic Cell Recovery and Anti-Tumor Effects after Syngeneic Bone Marrow Transplant (BMT).. <i>Blood</i> , 2005, 106, 1305-1305.	1.4	12
383	FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1341-1352.	2.0	11
384	In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination. <i>Stem Cells</i> , 2015, 33, 3174-3180.	3.2	11
385	Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 825-833.	2.0	11
386	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. <i>Clinical Cancer Research</i> , 2021, 27, 2712-2722.	7.0	11
387	Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213). <i>Blood</i> , 2020, 136, 45-46.	1.4	11
388	Induction of transplantation tolerance by combining non-myeloablative conditioning with delivery of alloantigen by T cells. <i>Clinical Immunology</i> , 2008, 127, 130-137.	3.2	10
389	STAT6 and Furin Are Successive Triggers for the Production of TGF- β 2 by T Cells. <i>Journal of Immunology</i> , 2018, 201, 2612-2623.	0.8	10
390	Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2190-2196.	2.0	10
391	Early Notch Signals Induce a Pathogenic Molecular Signature during Priming of Alloantigen-Specific Conventional CD4+ T Cells in Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2019, 203, 557-568.	0.8	10
392	Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality. <i>Journal of Immunology</i> , 2019, 202, 2795-2805.	0.8	10
393	Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid. <i>Modern Pathology</i> , 2019, 32, 560-567.	5.5	10
394	Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth. <i>Cancers</i> , 2021, 13, 3565.	3.7	10
395	Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. <i>Frontiers in Immunology</i> , 2021, 12, 757836.	4.8	10
396	Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for nonmalignant diseases. <i>Blood</i> , 2022, 139, 3583-3593.	1.4	10

#	ARTICLE	IF	CITATIONS
397	Cytolytic CD4+ and CD8+ Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2022, 13, 864748.	4.8	10
398	IL-33 acts as a costimulatory signal to generate alloreactive Th1 cells in graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	10
399	Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1541-1552.	4.2	9
400	Helminth-Induced Production of TGF- β 2 and Suppression of Graft-versus-Host Disease Is Dependent on IL-4 Production by Host Cells. <i>Journal of Immunology</i> , 2018, 201, 2910-2922.	0.8	9
401	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 56-62.	2.0	9
402	Targeting PI3K γ function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	4.7	9
403	PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment. <i>Frontiers in Immunology</i> , 2020, 11, 590568.	4.8	9
404	Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. <i>Bone Marrow Transplantation</i> , 2021, 56, 1238-1247.	2.4	9
405	Inflammasome effects in GvHD. <i>Oncotarget</i> , 2015, 6, 38444-38445.	1.8	9
406	Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD. <i>Blood Advances</i> , 2021, 5, 4578-4589.	5.2	9
407	Mechanisms by Which Obesity Promotes Acute Graft-Versus-Host Disease in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 752484.	4.8	9
408	Understanding Luminal Microorganisms and Their Potential Effectiveness in Treating Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 194-201.	1.9	8
409	A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression. <i>PLoS ONE</i> , 2018, 13, e0193461.	2.5	8
410	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. <i>Blood</i> , 2021, 137, 1090-1103.	1.4	8
411	Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects. <i>Blood</i> , 2021, 138, 2583-2588.	1.4	8
412	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. <i>JCI Insight</i> , 2019, 4, .	5.0	8
413	Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment. <i>Blood</i> , 2020, 136, 1-2.	1.4	8
414	Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. <i>Cell Death and Disease</i> , 2021, 12, 1005.	6.3	8

#	ARTICLE	IF	CITATIONS
415	Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial.. Blood, 2004, 104, 1825-1825.	1.4	8
416	Retinoic acid signaling acts as a rheostat to balance Treg function. , 2022, 19, 820-833.		8
417	Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. Cytotherapy, 2021, 23, 704-714.	0.7	7
418	Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control. Frontiers in Cell and Developmental Biology, 2021, 9, 737880.	3.7	7
419	Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant. Bone Marrow Transplantation, 2021, 56, 1373-1380.	2.4	7
420	KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208). Blood, 2019, 134, 872-872.	1.4	7
421	Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT. JCI Insight, 2021, 6, .	5.0	7
422	Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant. Blood Advances, 2020, 4, 4232-4243.	5.2	6
423	KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) â€” Pharmacodynamics and Updated Results. Blood, 2018, 132, 602-602.	1.4	6
424	Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation. Blood, 2010, 116, 225-225.	1.4	6
425	BET-bromodomain and EZH2 inhibitorâ€”treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood, 2022, 139, 2983-2997.	1.4	6
426	Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graftâ€”versusâ€”host disease: analysis of BMT CTNâ€”0201 and â€”0901 samples. British Journal of Haematology, 2018, 182, 887-894.	2.5	5
427	Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells. JCI Insight, 2021, 6, .	5.0	5
428	P63 targeted deletion under the FOXN1 promoter disrupts pre-and post-natal thymus development, function and maintenance as well as induces severe hair loss. PLoS ONE, 2022, 17, e0261770.	2.5	5
429	Reprint of: B Cells in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, S11-S18.	2.0	4
430	Regulatory T cell expressed MyD88 is critical for prolongation of allograft survival. Transplant International, 2016, 29, 930-940.	1.6	4
431	Thymic Epithelial Cell Support of Thymopoiesis Does Not Require Klotho. Journal of Immunology, 2018, 201, 3320-3328.	0.8	4
432	Early E. casseliflavus gut colonization and outcomes of allogeneic hematopoietic cell transplantation. PLoS ONE, 2019, 14, e0220850.	2.5	4

#	ARTICLE	IF	CITATIONS
433	An alpha-defensin gene single nucleotide polymorphism modulates the gut microbiota and may alter the risk of acute graft-versus-host disease. <i>British Journal of Haematology</i> , 2020, 189, 926-930.	2.5	4
434	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. <i>Blood Cancer Journal</i> , 2021, 11, 96.	6.2	4
435	NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death. <i>Blood</i> , 2019, 134, 3215-3215.	1.4	4
436	Host Indoleamine 2,3-Dioxygenase Is a Critical Regulator of Acute GVHD Lethality.. <i>Blood</i> , 2007, 110, 352-352.	1.4	4
437	Immune Reconstitution after Umbilical Cord Blood Versus Peripheral Blood Progenitor Cell Transplantation in Adults Following Myeloablative Conditioning. <i>Blood</i> , 2016, 128, 2246-2246.	1.4	4
438	Ex Vivo Blockade of NF- κ B Signaling in Alloreactive T Cells Prevents Murine Graft-Versus-Host Disease (GVHD).. <i>Blood</i> , 2004, 104, 3058-3058.	1.4	4
439	Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal. <i>Blood</i> , 2018, 132, 67-67.	1.4	4
440	Analyses and Correlation of Pathologic and Ocular Cutaneous Changes in Murine Graft versus Host Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 184.	4.1	4
441	Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 700.e1-700.e6.	1.2	4
442	Strategies to Inhibit Alloantibody Production in Alloprimed Murine Recipients of Hematopoietic Stem Cell Grafts. <i>American Journal of Transplantation</i> , 2015, 15, 931-941.	4.7	3
443	Cadherin 17 mutation associated with leaky severe combined immune deficiency is corrected by HSCT. <i>Blood Advances</i> , 2017, 1, 2083-2087.	5.2	3
444	Despite high levels of expression in thymic epithelial cells, miR-181a1 and miR-181b1 are not required for thymic development. <i>PLoS ONE</i> , 2018, 13, e0198871.	2.5	3
445	Shotgun sequencing of the faecal microbiome to predict response to steroids in patients with lower gastrointestinal acute graft-versus-host disease: An exploratory analysis. <i>British Journal of Haematology</i> , 2021, 192, e69-e73.	2.5	3
446	Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD). <i>Blood</i> , 2019, 134, 804-804.	1.4	3
447	Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair. <i>American Journal of Transplantation</i> , 2021, , .	4.7	3
448	Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802. <i>Blood</i> , 2017, 130, 72-72.	1.4	3
449	Divergent fates of antigen-specific CD8+ T cell clones in mice with acute leukemia. <i>Cell Reports</i> , 2021, 37, 109991.	6.4	3
450	Predictors and outcomes of flares in chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	3

#	ARTICLE	IF	CITATIONS
451	The E. Donnell Thomas Lecture. Biology of Blood and Marrow Transplantation, 2005, 11, 651-656.	2.0	2
452	Immune Regulatory Cell Biology and Clinical Applications to Prevent or Treat Acute Graft-Versus-Host Disease. Engineering, 2019, 5, 98-105.	6.7	2
453	An irradiated marrow niche reveals a small non-collagenous protein mediator of homing, dermatopontin. Blood Advances, 2021, 5, 3609-3622.	5.2	2
454	Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. Cancer Immunology, Immunotherapy, 1994, 38, 135-141.	4.2	2
455	Pharmacologic Blockade of Notch/Delta-like Ligand 4 Signaling Protects from Gastrointestinal Acute Graft-Versus-Host Disease in Non-Human Primates. Blood, 2018, 132, 2027-2027.	1.4	2
456	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. Blood, 2018, 132, 71-71.	1.4	2
457	PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets. Blood, 2019, 134, 621-621.	1.4	2
458	Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease. Blood, 2020, 136, 14-14.	1.4	2
459	Toll-Like Receptor 7-Targeting of Human B-Lineage Acute Lymphocytic Leukemia Induces Immunogenicity and Apoptosis of Leukemia Cells.. Blood, 2006, 108, 706-706.	1.4	2
460	Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells and Suppresses Circulating T Follicular Helper Cells in Patients with Chronic Gvhd. Blood, 2017, 130, 74-74.	1.4	2
461	Corticosteroid Treatment Impairs Epithelial Regeneration, Limiting Intestinal Recovery in Experimental Graft Vs Host Disease. Blood, 2021, 138, 88-88.	1.4	2
462	Regulatory T cells: A review of manufacturing and clinical utility. Transfusion, 2022, 62, 904-915.	1.6	2
463	High cutaneous amphiregulin expression predicts fatal acute <scp>graftâ€versusâ€host</scp> disease. Journal of Cutaneous Pathology, 2022, , .	1.3	2
464	Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. Bone Marrow Transplantation, 2018, 53, 1069-1071.	2.4	1
465	Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. Bone Marrow Transplantation, 2019, 54, 490-493.	2.4	1
466	Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Advances, 2020, 4, 2317-2324.	5.2	1
467	Activation Status Dictates the Function of Unlicensed Natural Killer Cells. Blood Advances, 2021, 5, 4219-4232.	5.2	1
468	First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 2112-2112.	1.4	1

#	ARTICLE	IF	CITATIONS
469	Innate Lymphoid Cell-Derived IL-22 Regulates Epithelial Recovery From Gvhd. Blood, 2012, 120, 339-339.	1.4	1
470	MiR-155 Impacts T Cell Migration in Acute Graft-Versus-Host Disease (aGVHD). Blood, 2015, 126, 3080-3080.	1.4	1
471	Mucocutaneous Engraftment and Type VII Collagen (C7) Replacement after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). Blood, 2015, 126, 402-402.	1.4	1
472	Stable Gene Transfer and Expression in Human Primary T-Cells by the Sleeping Beauty Transposon System.. Blood, 2005, 106, 5539-5539.	1.4	1
473	Correction of the Skin Defect in Murine Recessive Dystrophic Epidermolysis Bullosa by Bone Marrow Derived SLAM Family Receptor Enriched Cells.. Blood, 2007, 110, 435-435.	1.4	1
474	Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).. Blood, 2007, 110, 2160.5-2160.5.	1.4	1
475	iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo. Blood, 2019, 134, 1933-1933.	1.4	1
476	Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia. Blood, 2019, 134, 196-196.	1.4	1
477	Belumosudil for Patients with Chronic Graft-Versus-Host Disease: Combined Analysis of Failure-Free Survival (FFS) in the KD025-208 and Pivotal Rockstar Trials. Blood, 2021, 138, 3898-3898.	1.4	1
478	Single Agent CD45-Targeted Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model. Blood, 2020, 136, 31-31.	1.4	1
479	Treg tissue stability depends on lymphotoxin beta-receptor- and adenosine-receptor-driven lymphatic endothelial cell responses. Cell Reports, 2022, 39, 110727.	6.4	1
480	Distinct Roles for Donor and Host Antigen Presenting Cells and Costimulatory Molecules in Murine Chronic Graft-Vs-Host Disease: Requirements Depend on Target Organ.. Blood, 2004, 104, 3059-3059.	1.4	0
481	Reduced Intensity Compared to High Dose Conditioning for Allotransplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Comparative Clinical Analysis.. Blood, 2004, 104, 1817-1817.	1.4	0
482	Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. Blood, 2004, 104, 2148-2148.	1.4	0
483	Real-Time In Vivo Biodistribution of Multipotent Adult Progenitor Cells (MAPC): Role of the Immune System in MAPC Resistance in Non-Transplanted and Bone Marrow Transplanted Mice.. Blood, 2004, 104, 507-507.	1.4	0
484	In Vitro System for Generation of Leukemia-Specific Cytotoxic T Cells for Adoptive Immunotherapy.. Blood, 2005, 106, 1065-1065.	1.4	0
485	Mesenchymal Cancer Cells Can Arise from Ex Vivo Modified Mesenchymal Stem Cells.. Blood, 2005, 106, 4326-4326.	1.4	0
486	The Unexpected and Differential Effect of Cyclosporin A on CD56Bright and CD56Dim NK Cell Expansion, Phenotype, Function and Development from Progenitor Cells.. Blood, 2005, 106, 1404-1404.	1.4	0

#	ARTICLE	IF	CITATIONS
487	Removal of Donor CD4+ T Cells Markedly Promotes Graft-Versus-Tumor (GVT) Effects and Inhibits GVHD-Dependent Toxicity Associated with Prolonged Bortezomib Administration after Allogeneic BMT.. Blood, 2006, 108, 3160-3160.	1.4	0
488	Induction of Endogenous Repair Mechanisms by Single-Stranded DNA Oligonucleotide Therapy for Correction of the DNA-PK Mutation in Murine Severe Combined Immune Deficiency.. Blood, 2006, 108, 454-454.	1.4	0
489	Sleeping Beauty (SB) Transposon Mediated Umbilical Cord Blood (UCB) T Cell Therapy for Refractory Acute Lymphoblastic Leukemia (ALL).. Blood, 2006, 108, 722-722.	1.4	0
490	In Vivo CpG Administration Accelerates Graft-Versus-Host Disease (GVHD) Lethality by Toll-Like Receptor 9 (TLR9) Ligation of Host Antigen-Presenting Cells (APCs) and Promotes Allogeneic Bone Marrow (BM) Rejection by TLR9 Ligation of Donor APCs.. Blood, 2006, 108, 446-446.	1.4	0
491	Dissociating GVT from GVHD in Murine BMT Models through TNF α Dependent CD4+ T Cell Mediated GVHD and IFN γ Dependent CD8+ T Cell Mediated Anti-Tumor Effects.. Blood, 2007, 110, 69-69.	1.4	0
492	Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).. Blood, 2007, 110, 3951-3951.	1.4	0
493	Comparisons of the regulatory function of ex vivo expanded polyclonal or antigen-specific non-human primate T regulatory cells. FASEB Journal, 2008, 22, 862.16.	0.5	0
494	KGF and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution following murine BMT. FASEB Journal, 2008, 22, 536-536.	0.5	0
495	Treg Depletion with Interleukin-2-Diphtheriatoxin (IL-2DT) Is Sufficient to Induce Tumor Clearance in Acute Myeloid Leukemia (AML). Blood, 2008, 112, 2954-2954.	1.4	0
496	Critical and Opposing Effects of T Cell-Derived TNF α and Interferon- γ on IL-17 Induction Assessed in Vitro and in Vivo Following Allogeneic Bone Marrow Transplantation. Blood, 2008, 112, 3482-3482.	1.4	0
497	Tim-3, a Novel Immune Receptor, Is Constitutively Expressed on Human Natural Killer Cells and Functions as An Activating Coreceptor. Blood, 2010, 116, 106-106.	1.4	0
498	In Vitro Generation of NK22 Cells From Hematopoietic Stem Cells. Blood, 2010, 116, 108-108.	1.4	0
499	DNA Methylation Profile of Runx1 Regulatory Regions Is Correlated with Transition From Primitive to Definitive Hematopoietic Potential In Vitro and In Vivo. Blood, 2011, 118, 389-389.	1.4	0
500	Allogeneic Hematopoietic Cell Transplantation for Severe Epidermolysis Bullosa: Impact of Conditioning Regimen and Stem Cell Source On Outcomes. Blood, 2012, 120, 965-965.	1.4	0
501	A Randomized Trial of One Vs. Two Doses of Influenza Vaccine Following Allogeneic Transplantation. Blood, 2012, 120, 1896-1896.	1.4	0
502	Chronic GvHD Is Characterized By Impaired B Cell Development in the Bone Marrow. Blood, 2015, 126, 1883-1883.	1.4	0
503	Defining Successful Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2015, 126, 1934-1934.	1.4	0
504	Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells. Blood, 2016, 128, 808-808.	1.4	0

#	ARTICLE	IF	CITATIONS
505	Ex-Vivo Fucosylation Improves the Anti-Graft-Versus-Host-Disease Effects of Mesenchymal Stem Cells in the NOD/SCID/IL-2R Null Mouse Model. Blood, 2016, 128, 4559-4559.	1.4	0
506	Mechanism and Activity of ILC2 Cells Post Allo-BMT. Blood, 2016, 128, 1155-1155.	1.4	0
507	Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy. Blood, 2017, 130, 656-656.	1.4	0
508	A Critical Role for Donor-Derived IL-22 in Cutaneous Chronic Gvhd. Blood, 2017, 130, 69-69.	1.4	0
509	Uncovering the Molecular Signature of Pathogenic Tissue-Infiltrating T Cells during Acute Graft-Versus-Host Disease. Blood, 2018, 132, 805-805.	1.4	0
510	IL2 and Rapamycin Enhance Persistence of Adoptively-Transferred Ex-Vivo Expanded T Regulatory Cells. Blood, 2018, 132, 2049-2049.	1.4	0
511	ST2 and ROR- γ t Roles in Intestinal Regulatory T Cells. Blood, 2018, 132, 66-66.	1.4	0
512	Intestinal Immune Conditioning with Helminths Employs Host T Helper 2 (Th2) Pathway to Induce Mixed Chimerism and Regulate Graft-Versus-Host Disease. Blood, 2018, 132, 2036-2036.	1.4	0
513	Donor T Cells Require Notch Signals but Not Alloantigen Presentation from Specialized Secondary Lymphoid Organ Fibroblasts to Drive Graft-Versus-Host Disease. Blood, 2018, 132, 810-810.	1.4	0
514	Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprogramming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept. Blood, 2019, 134, 596-596.	1.4	0
515	Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 1922-1922.	1.4	0
516	Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD. Blood, 2019, 134, 3205-3205.	1.4	0
517	The Innate Immune Sensor Sting Promotes Donor CD8+ T Cell Activation and Recipient APC Death Early after Preclinical Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 3202-3202.	1.4	0
518	Dll1 and Dll4 Notch Ligands Prime T Cell Alloimmunity and Are Expressed in Non-Overlapping Populations of Fibroblastic Stromal Cells in Spleen and Lymph Nodes at the Onset of Gvhd. Blood, 2019, 134, 588-588.	1.4	0
519	Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT). Blood, 2019, 134, 2009-2009.	1.4	0
520	Galectin-3 Signaling in Donor T Cells Regulates Acute Graft Versus Host Disease (aGVHD) after Allogeneic Transplantation. Blood, 2021, 138, 2765-2765.	1.4	0
521	Prevention of Acute Graft-Versus-Host Disease Using an Engineered Mouse Orthogonal IL-2/IL-2R β Regulatory T Cells. Blood, 2021, 138, 1688-1688.	1.4	0
522	Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML. Blood, 2020, 136, 57-58.	1.4	0

#	ARTICLE	IF	CITATIONS
523	High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease. Blood, 2020, 136, 44-46.	1.4	0
524	Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease. Blood, 2020, 136, 47-48.	1.4	0
525	Predicting Immune Pathology after Hematopoietic Stem Cell Transplant with Transcriptomics: Naïve CD4 T Cell Expansion at Day 100 Predicts Patients with De Novo Chronic Gvhd. Blood, 2020, 136, 38-39.	1.4	0
526	Tissue-Derived IL-33 Is a Critical Local Signal That Targets Th1 Cells in the Small Intestine to Sustain Graft Versus Host Disease in the Absence of IL-12. Blood, 2020, 136, 1-2.	1.4	0
527	Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease. Frontiers in Immunology, 2022, 13, 765319.	4.8	0